Antibe Therapeutics Inc.
ATBPF · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Market Cap | $47,539 | $25,578 | $24,391 | $31,240 |
| - Cash | $11,339 | $4,143 | $8,793 | $6,755 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $36,200 | $21,435 | $15,598 | $24,485 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$4,211 | -$5,004 | -$5,368 | -$3,227 |
| % Margin | – | – | – | – |
| Net Income | -$4,213 | -$5,006 | -$5,786 | -$3,548 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.08 | -0.1 | -0.11 | -0.067 |
| % Growth | 20% | 9.1% | -63.2% | – |
| Operating Cash Flow | -$3,845 | -$6,432 | -$4,584 | -$3,384 |
| Capital Expenditures | $0 | $0 | $0 | $2 |
| Free Cash Flow | -$3,845 | -$6,432 | -$4,584 | -$3,382 |